Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own

Executive Summary

Nektar Therapeutics Inc. will launch the Phase III BEACON trial by the end of this year for its NKTR-102, a next-generation version of the now generic topoisomerase 1 inhibitor irinotecan (Pfizer Inc.’s Camptosar). The trial, in pretreated metastatic breast cancer patients, will have a raft of endpoints designed to help gain acceptance in the crowded field.

You may also be interested in...

Nektar Builds Case For Irinotecan-Inspired NKTR-102 In Cancer

Company’s R&D day stresses areas of unmet need for NKTR-102 in metastatic breast cancer. Company also highlights data from a Phase II study showing the drug’s promise in high-grade brain cancer.

Financings Of The Fortnight: Secondary Offerings Up From Pace Set In 2010 And 2011

Plus news on recent financings by Genkyotex, Synageva, Nektar Therapeutics and Edmond de Rothschild Investment Partners.

Quality-Of-Life Data Take On Added Significance With Avastin Debate

Among the many lessons that cancer drug sponsors should take away from the Avastin proceedings is that if they hope to secure approval on the basis of a progression-free survival endpoint, in certain settings, they need to bolster that data with quality-of-life assessments.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts